Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

Inclusion criteria

• Any one or more of the following characteristics will qualify patient with T2/T3 prostate cancer for eligibility to current study:
• Biopsy proven prostate cancer with Gleason score > 7
• Pathologic staging TXN1 (on MRI or CT)
• Prostate-specific antigen (PSA) > 10 ng/ml done within a month prior to study entry (the day of first hormonal ablation) and > 10 days after prostate biopsy.

In addition patients must also have:

• Performance status < 2
• Hemoglobin > 11 grams per deciliter (g/dL), White blood cell (WBC) > 4000 and platelet count > 100.000/l
• No evidence of other synchronous primary. Prior malignancies does not exclude if the patient is disease free > 5 years.
• Prior or concurrent basal cell or non-invasive squamous carcinoma of the skin is eligible and
• Received hormone therapy with any of the following combination for less than 3 months
• Lupron / Flutamide
• Zoladex/ Flutamide
• Lupron/ Casodex
• Zoladex/ Casodex

Exclusion criteria

• Clinical stage T1N0, PSA < 10, and Gleason score less than 7.
• Evidence of distant metastasis
• Previous surgery for prostate cancer (radical prostatectomy).
• Current treatment with ketoconazole, cimetidine or hormone therapy for more than 3 months prior to inclusion in the protocol for prostate cancer
• Major medical or psychiatric illness, which in the investigator's opinion may prevent completion of the study and interfere with follow up.
• Bilirubin > 1.5
• Prior chemotherapy is not allowed